Paula Ortega

Dr. Paula Ortega

CIBER-BBN, Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Journal of Controlled Release
Verified
Journal Article
Closed access
NWNick Weber
Nick Weber
POPaula Ortega
Paula Ortega
MCMaria Isabel Clemente
Maria Isabel Clemente
DSDzmitry Shcharbin
Dzmitry Shcharbin
MBMaria Bryszewska
Maria Bryszewska
María Angeles Muñoz FernándezMaría Angeles Muñoz Fernández
María Angeles Muñoz Fernández

19 December 2006 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
JBJesús F. Bermejo-Martin
Jesús F. Bermejo-Martin
POPaula Ortega
Paula Ortega
LCLouis Chonco
Louis Chonco
Ramon EritjaRamon Eritja
Ramon Eritja
RSRafael Samaniego
Rafael Samaniego
María Angeles Muñoz FernándezMaría Angeles Muñoz Fernández
María Angeles Muñoz Fernández

2 September 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ÁOÁngela Martín-Serrano Ortiz
Ángela Martín-Serrano Ortiz
RRRafael Gómez Ramírez
Rafael Gómez Ramírez
POPaula Ortega
Paula Ortega
FMFrancisco Javier De La Mata
Francisco Javier De La Mata
Recently, antimicrobial peptides (AMPs), also called host defence peptides (HDPs), are attracting great interest, as they are a highly viable alternative in the search of new approaches to the resistance presented by bacteria against antibiotics in infectious diseases. However, due to their nature, they present a series of disadvantages such as low bioavailability, easy degradability by proteases, or low solubility, among others, which limits their use as antimicrobial agents. For all these reasons, the use of vehicles for the delivery of AMPs, such as polymers, nanoparticles, micelles, carbon nanotubes, dendrimers, and other types of systems, allows the use of AMPs as a real alternative to treatment with antibiotics.

4 February 2009 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
IPInmaculada Posadas
Inmaculada Posadas
BLBeatriz López-Hernández
Beatriz López-Hernández
MCMaria Isabel Clemente
Maria Isabel Clemente
JJJose Luis Jiménez
Jose Luis Jiménez
POPaula Ortega
Paula Ortega
VCValentín Ceña
Valentín Ceña

29 July 2008 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
POPaula Ortega
Paula Ortega
JPJosé Luis Copa Patiño
José Luis Copa Patiño
María Angeles Muñoz FernándezMaría Angeles Muñoz Fernández
María Angeles Muñoz Fernández
JSJuan Soliveri
Juan Soliveri
RGRafael Gomez
Rafael Gomez
FMFrancisco Javier De La Mata
Francisco Javier De La Mata
Novel amine- and ammonium-terminated carbosilane dendrimers of type Gn-[Si{CH2O-(C6H4)-3-NMe2}]x or Gn-[Si{CH2O-(C6H4)-3-NMe3 +I−}]x have been synthesized and characterized up to second generation by phenolysis of (chloromethyl)silyl-terminated dendrimers with 3-dimethylamine phenol and subsequent quaternization with methyl iodide. Quaternized carbosilane dendrimers are stable in protic solvents and can be solubilised in water after the addition of less than 1% of dimethyl sulfoxide. A study of the antimicrobial activity of these cationic dendrimers of first and second generation against both Gram-positive and Gram-negative bacteria is also described. The results obtained demonstrate that the new ammonium-terminated carbosilane dendrimers can be considered as multivalent biocides.

1 October 2010 in BioDrugs
Verified
Journal Article
Closed access
PDF file
JJJose Luis Jiménez
Jose Luis Jiménez
MCMaría Isabel Clemente
María Isabel Clemente
NWNick D. Weber
Nick D. Weber
JSJavier Sanchez
Javier Sanchez
POPaula Ortega
Paula Ortega
María Angeles Muñoz FernándezMaría Angeles Muñoz Fernández
María Angeles Muñoz Fernández